New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 7, 2014
09:02 EDTPIPPharmAthene receives notice advising company of of SparVax anthrax vaccine
PharmAthene announced that it has received notice from the Department of Health and Human Services, Biomedical Advanced Research and Development Authority, advising the company of its decision to de-scope the current SparVax anthrax vaccine contract through a partial termination for convenience. BARDA will provide additional guidance to PharmAthene on the contractual changes, following which PharmAthene will evaluate its options with respect to its SparVax program. PharmAthene has been developing SparVax to address a requirement for a modern anthrax vaccine based on state-of-the-art vaccine technology. Phase 1 and Phase 2 clinical trials involving 770 healthy subjects have demonstrated that SparVax appears to be well tolerated and capable of producing an immune response in humans.
News For PIP From The Last 14 Days
Check below for free stories on PIP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
09:25 EDTPIPOn The Fly: Pre-market Movers
Subscribe for More Information
September 11, 2014
07:25 EDTPIPAegis to hold a conference
Subscribe for More Information
September 10, 2014
09:07 EDTPIPPharmAthene awarded $28.1M contract by NIAID
Subscribe for More Information
September 9, 2014
09:08 EDTPIPPharmAthene presented non-clinical animal data on SparVax anthrax vaccine
PharmAthene announced that recent non-clinical animal data from its SparVax anthrax vaccine program were presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, or ICAAC, in Washington, DC. In a poster presentation Dr. Sherry Crowe, Director, Immunology for PharmAthene, presented an overview of non clinical animal studies of SparVax showing, among other things, that it can induce dose-dependent protective immunity in the established rabbit model for inhalational anthrax, and was statistically non-inferior to the currently licensed anthrax vaccine, BioThrax, when comparing survival and toxin neutralization assay results from the nonclinical anthrax aerosol challenge model.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use